Lamotrigine Tablet, Film Coated, Extended Release
Product Images NDC 70518-4638

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 70518-4638). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Mm1 (Lamotrigine 200mg 70518 4638 00)

Mm1 (Lamotrigine 200mg 70518 4638 00)
Lamotrigine extended-release 200 mg tablets film coated, packaged 50 per box. The label shows the brand Remedy Repack and includes storage instructions, NDC number 70518-4638-00, and repackager information RemedyRepack Inc., Indiana, PA. Manufacturer is Camber Pharma, Inc., Piscataway, NJ.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Lamotrigine 200 mg extended-release film-coated tablet, package of 1 tablet. The label shows the brand name Lamotrigine Tablet, extended-release, with strength 200 mg highlighted. It is repackaged by RemedyRepack Inc., Indiana, PA. Storage instructions and manufacturer info (Camber Pharma, Inc.) are also visible, along with the NDC number 70518-4638-01.*
FDA Label Image

Figure 1. Proportion Of Patients By Responder Rate For Lamotrigine And Placebo Group (primary Generalized Tonic-clonic Seizures Study) (Figure 1)

Figure 1. Proportion Of Patients By Responder Rate For Lamotrigine And Placebo Group (primary Generalized Tonic-clonic Seizures Study) (Figure 1)
A line graph depicting responder rates (equal or greater improvement vs. worsening) on the vertical axis and percent of patients on the horizontal axis, comparing lamotrigine extended-release (solid line) to placebo (dashed line) groups. The graph illustrates cumulative responder rates for 70 patients on lamotrigine and 73 on placebo.*
FDA Label Image

Figure 2. Proportion Of Patients By Responder Rate For Lamotrigine And Placebo Group (partial-onset Seizure Study) (Figure 2)

Figure 2. Proportion Of Patients By Responder Rate For Lamotrigine And Placebo Group (partial-onset Seizure Study) (Figure 2)
A cumulative distribution graph showing the responder rate (equal or greater improvement to worsening) plotted against the percent of patients for lamotrigine versus placebo. The chart includes a solid line for lamotrigine (N=116) and a dashed line for placebo (N=120), with the x-axis labeled as percent of patients (100 to 0) and the y-axis labeled with responder rate percentages from -100% to 100%.*
FDA Label Image

Chemical Structure (Graphic 01)

Chemical Structure (Graphic 01)
Chemical structure of lamotrigine, shown as a molecular diagram with labeled rings and chlorine atoms, corresponding to the active ingredient in lamotrigine extended-release tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.